- Home
- CPHC vs SLS Comparison
CPHC vs SLS Comparison
Compare CPHC & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPHC
- SLS
- Stock Information
- Founded
- CPHC 1994
- SLS 2012
- Country
- CPHC United States
- SLS United States
- Employees
- CPHC N/A
- SLS N/A
- Industry
- CPHC Services-Misc. Amusement & Recreation
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- CPHC Consumer Discretionary
- SLS Health Care
- Exchange
- CPHC Nasdaq
- SLS Nasdaq
- Market Cap
- CPHC 102.1M
- SLS 88.8M
- IPO Year
- CPHC 1994
- SLS N/A
- Fundamental
- Price
- CPHC $19.50
- SLS $1.16
- Analyst Decision
- CPHC
- SLS
- Analyst Count
- CPHC 0
- SLS 0
- Target Price
- CPHC N/A
- SLS N/A
- AVG Volume (30 Days)
- CPHC 2.1K
- SLS 1.1M
- Earning Date
- CPHC 03-10-2025
- SLS 03-27-2025
- Dividend Yield
- CPHC 1.43%
- SLS N/A
- EPS Growth
- CPHC N/A
- SLS N/A
- EPS
- CPHC 0.42
- SLS N/A
- Revenue
- CPHC $61,562,288.00
- SLS N/A
- Revenue This Year
- CPHC N/A
- SLS N/A
- Revenue Next Year
- CPHC N/A
- SLS N/A
- P/E Ratio
- CPHC $46.62
- SLS N/A
- Revenue Growth
- CPHC 0.20
- SLS N/A
- 52 Week Low
- CPHC $18.05
- SLS $0.77
- 52 Week High
- CPHC $24.78
- SLS $1.84
- Technical
- Relative Strength Index (RSI)
- CPHC 37.28
- SLS 45.67
- Support Level
- CPHC $19.00
- SLS $1.11
- Resistance Level
- CPHC $20.36
- SLS $1.21
- Average True Range (ATR)
- CPHC 0.31
- SLS 0.07
- MACD
- CPHC -0.14
- SLS -0.01
- Stochastic Oscillator
- CPHC 19.31
- SLS 37.50
About CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.